Otsuka Pharmaceutical Companies (U.S.)’s Post

Did you miss Avance Clinical's live Psychedelics In Focus webinar on Monday? The webinar featured a fascinating conversation between Senior Director of Scientific and Regulatory Services, Jorgen Mould and Senior Vice President Scientific and Regulatory Affairs Kevin Leach, Ph.D, DABT. Delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder. Simply register via the Xtalks website 👇 https://lnkd.in/eywUiP3i #AvanceClinical #CRO #psychedelicscience #psychedelicresearch #clinicalresearch #newmedicines #depression #anxiety #webinar

VA Funds Studies on New Therapies for Treating Mental Health Conditions   The VA has released a request for applications (RFA) inviting proposals from its network of VA researchers, in collaboration with academic institutions, to study the use of psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in treating posttraumatic stress disorder (PTSD) and depression. This marks the first time since the 1960s that the VA is funding research on these compounds. The initiative aims to gather definitive scientific evidence on the potential efficacy and safety of psychedelic compounds when used in conjunction with psychotherapy to treat veterans with PTSD and depression. The move is part of the VA's commitment to exploring innovative approaches to improve the health and quality of life for veterans, aligning with the Biden-Harris Administration's focus on veterans' well-being. Research on these compounds will be conducted under stringent safety protocols and regulatory approvals from the United States Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).

🚨 BREAKING NEWS 🚨 Multidisciplinary Association for Psychedelic Studies (MAPS) has finally published their much-anticipated MAPP2 Phase 3 MDMA trial results, and the news is next level. The MAPP2 study evaluated the efficacy and safety of MDMA-assistant therapy for PTSD, and successfully showed that participants in the study experienced a clinically meaningful improvement, with many participants even no longer meeting the diagnostic requirements for PTSD, and over 80% experiencing a more than 10 point severity score reduction in total severity score. There were no serious safety incidents reported, nor any issues with abuse or dependency. This is major news for the psych world, and this publication of such positive Phase 3 results is a significant step forward towards submitting a new drug application to the FDA in 2023. We’ll be going live on YouTube around 4 p.m. EST to discuss this huge development. Be sure to tune in 👀 https://lnkd.in/g93pFFaC #ptsd #psychedelics #psychedelictherapy #psychedelicresearch #mdma

LIVE WEBINAR 💻 💊 Monday November 27 10am PST / 12pm CST / 1pm EST (US TIME) Please join us for an informative webinar as we delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder. Our expert panellists Jorgen Mould and Kevin Leach, Ph.D, DABT will provide invaluable insights into ongoing trials, innovations in psychedelic therapies, and the regulatory pathways shaping the future of mental health treatment. Don’t miss this opportunity to stay informed about the latest developments in psychedelic research and regulatory advancements. Secure your spot now for this enlightening webinar with Avance Clinical. Register now! 👇 https://lnkd.in/gpKgjCYM #AvanceClinical #CRO #clinicaltrials #drugdevelopment #psychedelics #psilocybin #depression #anxiety #PTSD #addiction #webinar #biotech

💪 If we can, we must, and we should.......we need to improve treatments for depression and related mental health conditions urgently! 🔥 That's exactly what we've set out to do in this important work and the data is starting to look overwhelmingly compelling that we have a scalable treatment solution in microdosing MB22001 to treat depression. Of course, more evidence and work is required so MindBio is progressing to late stage clinical trials. 😀 MindBio's Phase 2B take-home microdosing MB22001 trial in patients with Major Depressive Disorder has been given the final regulatory go ahead and will start dosing first patients on 11 March 2024.

What is TMS used for? 🔎 In Australia, TMS is currently TGA-approved for the treatment of depression, with Medicare rebates now available for eligible* adult patients that have tried two or more antidepressant medications without any significant benefits to their symptoms. It is generally used for those patients who do not see improvements from other treatments. TMS may also help patients with other conditions, such as OCD, PTSD, pain management and tinnitus, with evidence continuing to emerge for a range of psychiatric and neurological conditions. 👉 For more information on TMS and how it works, visit our website at www.modalis.com.au or email our friendly team at [email protected]. #tms #tmstherapy #tmsaustralia #rtms #transcranialmagneticstimulation #repetitivetranscranialmagneticstimulation #brainstimulation #neuroscienceaustralia #perthclinic #perth

My dad was a veteran and police officer who died by suicide due to chronic pain. Veterans, police, and those struggling with pain may not have considered psychotherapy to manage their pain. A new study (June 13, JAMA Network Open, "A New Psychotherapeutic 'Gold Standard' for Chronic Pain?") found that a single course of treatment with emotional awareness and expression therapy (EAET) was associated with a significantly greater reduction in chronic pain severity than cognitive-behavioral therapy (CBT). The study compared EAET with CBT. Two-thirds of patients who received EAET reported a 30% reduction in pain, compared with 17% of those who received CBT. Those with depression and anxiety responded more favorably to EAET. In EAET, they were asked to recall a difficult or traumatic memory, engage in experiencing how emotions feel in the body, express feelings, and let them go. This contrasts with CBT, the current gold standard for chronic pain. CBT focuses on tolerating pain through guided imagery, muscle relaxation, and exercises, and adapting thinking to change thinking about pain. The trial enrolled 126 veterans (92% men; 55% black or African American) aged 60–95 years with at least 3 months of musculoskeletal pain. More than two-thirds of individuals had a psychiatric diagnosis; one-third had PTSD. Almost all had back pain, and many had pain in multiple locations. The study demonstrated that expressing emotions is superior to the cognitive discussion of these emotions in the therapy of patients with chronic pain. #Compassionfatigue #vicarioustrauma #suicideprevention #veterans #mentalhealth #painmanagement

Xanomeline-trospium is efficacious & well tolerated in people with schizophrenia experiencing acute psychosis, finds EMERGENT-3 trial, and supports potential of xanomeline-trospium to be first in a putative new class of antipsychotic medications. https://ja.ma/3UqjnDs

June is #PTSDAwarenessMonth and it's crucial to spread the word that treatments can significantly improve quality of life. Our expertise and innovative technology help study teams recognize, diagnose, and assess changes in PTSD patients. Learn more: https://hubs.li/Q02CP7_w0